IL6 and COVID-19: In our study, Remdesivir and Lopinavir as antiviral treatments, and Tocilizumab as an Il-6 inhibitor, were administered to the COVID-19 group in accordance with international protocols from the time of data collection and on the recommendation of the infectious disease physician [24,25].